PTC Therapeutics, Inc.

378 articles with PTC Therapeutics, Inc.

• PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2019 Financial Results

  10/15/2019

  2019 financial results and provide an update on the company's business and outlook on Tuesday, October 29, 2019 at 4:30 p.m. (ET) after closing of the market.

• PTC Therapeutics Establishes Strategic Collaboration with Aldevron to Support GMP Plasmid Manufacturing

  10/7/2019

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a collaboration with Aldevron, LLC to secure GMP manufacturing capacity for PTC's gene therapy portfolio, including the Friedreich ataxia and Angelman syndrome programs in PTC's growing gene therapy pipeline.   

• PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna™ (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy

  10/4/2019

  Lung function data from the STRIDE Registry show a trend toward delay of decline of pulmonary function compared with those in CINRG Duchenne Natural History1

• Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress

  10/2/2019

  PTC Therapeutics, Inc. announced data demonstrating the ongoing benefit of risdiplam (RG7916) for the treatment of all types of spinal muscular atrophy (SMA) at the 24th International Annual Congress of the World Muscle Society.

• PTC Therapeutics to Participate at Upcoming Investor Conferences - Sept. 27, 2019

  9/27/2019

  PTC Therapeutics, Inc. announced that management will present a company update at the following conferences

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sept. 20, 2019

  9/20/2019

  PTC Therapeutics, Inc. announced that on September 18, 2019 it approved non-statutory stock options to purchase an aggregate of 211,500 shares of its common stock to 48 new employees.

• PTC Therapeutics Announces Pricing of Private Offering of Convertible Senior Notes

  9/18/2019

  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it has priced its private offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes").

• PTC Therapeutics Announces Pricing of Public Offering of Common Stock - Sept. 18, 2019

  9/18/2019

  PTC Therapeutics, Inc. announced the pricing of a public offering of 2,475,248 shares of its common stock at a public offering price of $40.40 per share, before underwriting discounts and commissions.

• PTC Therapeutics Announces Proposed Public Offering of Common Stock - Sept. 17, 2019

  9/17/2019

  PTC Therapeutics, Inc. announced that it is commencing a public offering of $100.0 million of shares of its common stock.

• PTC Therapeutics Announces Proposed Private Offering of Convertible Senior Notes

  9/17/2019

  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing an offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"), subject to market conditions and other factors.

• PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award Winners

  9/6/2019

  PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2019 global STRIVE Awards program, designed to support non-profit organizations serving the Duchenne muscular dystrophy community. 

• PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

  8/6/2019

  Translarna™ approved in Brazil & PTC entered first annual contract with Ministry of Health

• PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility

  8/5/2019

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has signed a long-term lease agreement with Bristol-Myers Squibb Company (NYSE: BMY)

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 31, 2019

  7/31/2019

  PTC Therapeutics, Inc. announced that on July 26, 2019 it approved non-statutory stock options to purchase an aggregate of 208,100 shares of its common stock to 72 new employees.

• PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2019 Financial Results

  7/23/2019

  PTC Therapeutics, Inc. announced that the Company will host a webcast conference call to report its second quarter 2019 financial results and provide an update on the company's business and outlook on Tuesday, August 6, 2019 at 4:30 p.m. after closing of the market.

• PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics

  7/1/2019

  Collaboration expands PTC's Gene Therapy portfolio to rare ophthalmic diseases

• PTC Provides Update on Translarna™ (ataluren) Application for Label Expansion

  6/28/2019

  PTC Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has completed their review of a proposed indication extension of Translarna™ for the treatment of patients with nonsense mutation Duchenne muscular dystrophy who are non-ambulatory.

• PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age

  6/7/2019

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Emflaza® (deflazacort) to expand its labeling to include patients with Duchenne muscular dystrophy who are between 2- and 5-years-old

• PTC Therapeutics Promotes Emily Hill to Chief Financial Officer

  6/3/2019

  PTC Therapeutics, Inc. today announced the promotion of Emily Hill to Chief Financial Officer.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 31, 2019

  5/31/2019

  PTC Therapeutics, Inc. announced that on May 20, 2019 it approved non-statutory stock options to purchase an aggregate of 76,250 shares of its common stock to 15 new employees.